Alternative to the soft-agar assay that permits high-throughput drug and genetic screens for cellular transformation
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Significance: The paper describes an assay for cellular transformation that involves growth in low attachment (GILA). This assay is comparable to the gold-standard soft-agar assay, but it is much easier to perform and is suitable for high-throughput drug and genetic screens. We describe such screens for drugs and genes that selectively inhibit or increase transformation, but not proliferation. Such molecules are unlikely to be found through conventional drug screening. Lastly, we demonstrate the ability of Food and Drug Administration-approved noncancer drugs to selectively kill ovarian cancer cells derived from patients with chemotherapy-resistant disease, suggesting this approach may provide useful information for personalized cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In that screen, across four replicates, the pairwise correlations ranged from 0.18 to 0.20.”
From Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities (2018) · cites this paper as [60]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The third dimension bridges the gap between cell culture and live tissue
Pampaloni, F., Reynaud, E. G., & Stelzer, E. H. K. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2236 · Cited by 2,817
Creation of human tumour cells with defined genetic elements
Hahn, W. C., Counter, C. M., Lundberg, A. S., Beijersbergen, R. L., Brooks, M. W., & Weinberg, R. A. (1999) · Nature · doi:10.1038/22780 · Cited by 2,345
Hirsch, H. A., Iliopoulos, D., Tsichlis, P. N., & Struhl, K. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2994 · Cited by 1,115
Self-citationShin, S. I., Freedman, V. H., Risser, R., & Pollack, R. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.11.4435 · Cited by 738 · cited 1×
“F nearly 50 y (1, 2), the gold-standard assay for cellular transformation/tumorigenicity has been the soft-agar assay.”
A public genome-scale lentiviral expression library of human ORFs
Yang, X., Boehm, J. S., Yang, X., Salehi-Ashtiani, K., Hao, T., Shen, Y., Lubonja, R., Thomas, S. R., Alkan, O., Bhimdi, T., et al. (2011) · Nature Methods · doi:10.1038/nmeth.1638 · Cited by 570 · cited 3×
“MCF-10A cells were infected with a library of barcoded ORFs (21) at a low (<1) multiplicity, with an average of 1,000 cells per ORF clone, and infected cells were selected with puromycin for 5 d.”
MethodMulticellular spheroids in ovarian cancer metastases: Biology and pathology
Shield, K., Ackland, M. L., Ahmed, N., & Rice, G. E. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.11.032 · Cited by 412 · cited 1×
“Compared with cells grown in 2D monolayers attached to plates, such 3D growth conditions more accurately reflect the natural environment of cancer cells (3) and are crucial to be performed before animal studies (4, 5).”
Background
Cited by
Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities
Sanson, K. R., Hanna, R. E., Hegde, M., Donovan, K. F., Strand, C., Sullender, M. E., Vaimberg, E. W., Goodale, A., Root, D. E., Piccioni, F., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07901-8 · Cited by 1,043
Self-citationZou, Y., Palte, M. J., Deik, A. A., Li, H., Eaton, J. K., Wang, W., Tseng, Y.-Y., Deasy, R., Kost-Alimova, M., Dančík, V., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09277-9 · Cited by 887
Self-citationA single-cell landscape of high-grade serous ovarian cancer
Izar, B., Tirosh, I., Stover, E. H., Wakiro, I., Cuoco, M. S., Alter, I., Rodman, C., Leeson, R., Su, M.-J., Shah, P., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0926-0 · Cited by 504
Self-citationAm I ready for CRISPR? A user's guide to genetic screens
Doench, J. G. (2018) · Nature Reviews Genetics · doi:10.1038/nrg.2017.97 · Cited by 452
Self-citationThe production of 3D tumor spheroids for cancer drug discovery
Sant, S., & Johnston, P. A. (2017) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2017.03.002 · Cited by 404
Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies
Guièze, R., Liu, V. M., Rosebrock, D., Jourdain, A. A., Hernández-Sánchez, M., Martinez Zurita, A., Sun, J., Ten Hacken, E., Baranowski, K., Thompson, P. A., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.08.005 · Cited by 361
Self-citationOrthologous CRISPR–Cas9 enzymes for combinatorial genetic screens
Najm, F. J., Strand, C., Donovan, K. F., Hegde, M., Sanson, K. R., Vaimberg, E. W., Sullender, M. E., Hartenian, E., Kalani, Z., Fusi, N., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4048 · Cited by 279
“7b); the latter are a surrogate for soft agar and select for transformation phenotypes 46 .”
Self-citationExploring Targeted Degradation Strategy for Oncogenic KRASG12C
Zeng, M., Xiong, Y., Safaee, N., Nowak, R. P., Donovan, K. A., Yuan, C. J., Nabet, B., Gero, T. W., Feru, F., Li, L., et al. (2020) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.12.006 · Cited by 275
Ji, Z., He, L., Regev, A., & Struhl, K. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821068116 · Cited by 219
“S1B) cause decreased transformation as assayed by growth under conditions of low attachment (16) (SI Appendix, Fig.”
BackgroundSelf-citationThree‐dimensional cell culture models for anticancer drug screening: Worth the effort?
Verjans, E., Doijen, J., Luyten, W., Landuyt, B., & Schoofs, L. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26052 · Cited by 212
He, L., Pratt, H., Gao, M., Wei, F., Weng, Z., & Struhl, K. (2021) · eLife · doi:10.7554/elife.67312 · Cited by 122
Self-citationMassively parallel phenotyping of coding variants in cancer with Perturb-seq
Ursu, O., Neal, J. T., Shea, E., Thakore, P. I., Jerby-Arnon, L., Nguyen, L., Dionne, D., Diaz, C., Bauman, J., Mosaad, M. M., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-021-01160-7 · Cited by 96
Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers
Sulahian, R., Kwon, J. J., Walsh, K. H., Pailler, E., Bosse, T. L., Thaker, M., Almanza, D., Dempster, J. M., Pan, J., Piccioni, F., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.090 · Cited by 90
Theard, P. L., Sheffels, E., Sealover, N. E., Linke, A. J., Pratico, D. J., & Kortum, R. L. (2020) · eLife · doi:10.7554/elife.58204 · Cited by 69
“, 2014) still require KRAS for anchorage-independent growth (Fujita-Sato et al., 2015; Rotem et al., 2015; Zhang et al., 2006; McCormick, 2015), and some KRAS-mutated NSCLC cell lines respond to KRAS(G12C) inhibitors in 3D culture and in vivo but not in 2D adherent culture (Janes et al.”
BackgroundThe role of wild-type RAS in oncogenic RAS transformation
Sheffels, E., & Kortum, R. L. (2021) · Genes · doi:10.3390/genes12050662 · Cited by 42
Polymer Thin Film-Induced Tumor Spheroids Acquire Cancer Stem Cell-like Properties
Choi, M., Yu, S. J., Choi, Y., Lee, H. R., Lee, E., Lee, E., Lee, Y., Song, J., Son, J. G., Lee, T. G., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0927 · Cited by 32
Metadata
- Authors
- Rotem, A., Janzer, A., Izar, B., Ji, Z., Doench, J. G., Garraway, L. A., & Struhl, K.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2015-04-20
- Volume
- 112
- Issue
- 18
- Pages
- 5708-5713
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2071006154
- Cited by
- 126
- References
- 6
- FWCI
- 5.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.